Resistance analysis of the hepatitis C virus NS5A inhibitor BMS-790052 in an in vitro replicon system.

@article{Fridell2010ResistanceAO,
  title={Resistance analysis of the hepatitis C virus NS5A inhibitor BMS-790052 in an in vitro replicon system.},
  author={Robert A. Fridell and Dike Qiu and Chunfu Wang and Lourdes L Valera and Min Gao},
  journal={Antimicrobial agents and chemotherapy},
  year={2010},
  volume={54 9},
  pages={
          3641-50
        }
}
BMS-790052 is the most potent hepatitis C virus (HCV) inhibitor reported to date, with 50% effective concentrations (EC(50)s) of < or = 50 pM against genotype 1 replicons. This exceptional potency translated to rapid viral load declines in a phase I clinical study. By targeting NS5A, BMS-790052 is distinct from most HCV inhibitors in clinical evaluation. As an initial step toward correlating in vitro and in vivo resistances, multiple cell lines and selective pressures were used to identify BMS… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 143 CITATIONS

FILTER CITATIONS BY YEAR

2010
2018

CITATION STATISTICS

  • 23 Highly Influenced Citations

  • Averaged 14 Citations per year over the last 3 years

References

Publications referenced by this paper.
SHOWING 1-10 OF 39 REFERENCES

Chemical genetics strategy identifies an HCV NS 5 A inhibitor with a potent clinical efficacy

  • X. Hanoulle, D. Verdegem, A. Badillo, J. M. Wieruszeski, F. Penin, G. Lippens
  • Nature
  • 2010

Similar Papers

Loading similar papers…